# A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

> **NCT04981665** · PHASE2 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 50 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Adjuvant Therapy

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** TACE

## Key facts

- **NCT ID:** NCT04981665
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-08
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-01-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04981665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04981665, "A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04981665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*